Mehdi Bouhaddou

List of Publications by Year
in descending order

27	6,762	516215 16	610482 24
papers	citations	h-index	g-index
42	42	42	13136
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature, 2020, 583, 459-468.	13.7	3,542
2	The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell, 2020, 182, 685-712.e19.	13.5	825
3	Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science, 2020, 370, .	6.0	508
4	Genetic Screens Identify Host Factors for SARS-CoV-2 and Common Cold Coronaviruses. Cell, 2021, 184, 106-119.e14.	13.5	320
5	Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. Science, 2021, 371, 926-931.	6.0	247
6	Evolution of enhanced innate immune evasion by SARS-CoV-2. Nature, 2022, 602, 487-495.	13.7	237
7	Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission. Cell Host and Microbe, 2022, 30, 373-387.e7.	5.1	138
8	A protein interaction landscape of breast cancer. Science, 2021, 374, eabf3066.	6.0	66
9	Drug response consistency in CCLE and CGP. Nature, 2016, 540, E9-E10.	13.7	64
10	A Comparison of mRNA Sequencing with Random Primed and 3â€²-Directed Libraries. Scientific Reports, 2017, 7, 14626.	1.6	52
11	A mechanistic pan-cancer pathway model informed by multi-omics data interprets stochastic cell fate responses to drugs and mitogens. PLoS Computational Biology, 2018, 14, e1005985.	1.5	45
12	The Landscape of Human Cancer Proteins Targeted by SARS-CoV-2. Cancer Discovery, 2020, 10, 916-921.	7.7	44
13	A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity. Science, 2021, 374, eabf2911.	6.0	37
14	Engineered Mammalian RNAi Can Elicit Antiviral Protection that Negates the Requirement for the Interferon Response. Cell Reports, 2015, 13, 1456-1466.	2.9	32
15	A functional map of HIV-host interactions in primary human T cells. Nature Communications, 2022, 13, 1752.	5.8	27
16	Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19. Life Science Alliance, 2022, 5, e202101200.	1.3	26
17	Integrating Transcriptomic Data with Mechanistic Systems Pharmacology Models for Virtual Drug Combination Trials. ACS Chemical Neuroscience, 2018, 9, 118-129.	1.7	17
18	Predicting *In Vivo* Efficacy from *In Vitro* Data: Quantitative Systems Pharmacology Modeling for an Epigenetic Modifier Drug in Cancer. Clinical and Translational Science, 2020, 13, 419-429.	1.5	16

#	Article	IF	Citations
19	Dimerization-based control of cooperativity. Molecular BioSystems, 2014, 10, 1824-1832.	2.9	15
20	Fluorescence Multiplexing with Spectral Imaging and Combinatorics. ACS Combinatorial Science, 2018, 20, 653-659.	3.8	15
21	Mapping the protein–protein and genetic interactions of cancer to guide precision medicine. Current Opinion in Genetics and Development, 2019, 54, 110-117.	1.5	15
22	Validating Antibodies for Quantitative Western Blot Measurements with Microwestern Array. Scientific Reports, 2018, 8, 11329.	1.6	14
23	Analysis of copy number loss of the ErbB4 receptor tyrosine kinase in glioblastoma. PLoS ONE, 2018, 13, e0190664.	1.1	10
24	Leveraging modeling and simulation to optimize the therapeutic window for epigenetic modifier drugs. , 2022, 235, 108162.		5
25	Kinetic Models of Biochemical Signaling Networks. AAPS Advances in the Pharmaceutical Sciences Series, 2016, , 105-135.	0.2	1
26	Abstract 1568: Predicting stochastic proliferation and death in response to drugs with mechanistic models tailored to genomic, transcriptomic, and proteomic data. , 2017, , .		0
27	Abstract 2796: Predicting in vivo efficacy from in vitro data: Quantitative systems pharmacology modeling for an epigenetic modifier drug in cancer. , 2018, , .		0